secwatch.observer — SEC 8-K summary
======================================

Issuer:     Omega Therapeutics, Inc. (—)
CIK:        0001850838
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001193125-25-019359
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 1.02, 2.03, 3.01, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Omega Therapeutics enters RSA for Chapter 11, plans asset sale after loan default
--------------------------------------------------------------------------------

- Entered Restructuring Support Agreement with Flagship affiliate for $1.4M bridge loan and DIP loan to fund Chapter 11 process.
- Plans to file Chapter 11 by Feb 10, 2025; seeks Bankruptcy Court approval for stalking horse asset sale to Supporting Party.
- Received Nasdaq delisting notice for bid price below $1; has until July 28, 2025 to regain compliance.
- Loan from Banc of California terminated after default notice and setoff of $14.7M; company believes default not valid.
- Approved workforce reduction of up to 17 employees and retention bonuses for CEO ($40K) and CAO ($81.4K).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/0001193125-25-019359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850838/000119312525019359/d927659d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-019359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer